CRNX Institutional Investor Snapshot (243 Funds)

Crinetics Pharmaceuticals (CRNX) entered into a merger agreement with Vertex Pharmaceuticals on July 6, 2026, as part of which Vertex will acquire the company. In connection with the merger, Crinetics signed one-year non-compete agreements with its CEO, CFO, Chief Scientific Officer, and Chief Commercial Officer. The CFO, Chief Scientific Officer, and Chief Commercial Officer will receive cash payments of $140,000, $30,000, and $30,000, respectively, when the deal closes.

Crinetics Pharmaceuticals has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals in an all-cash deal. Shareholders will receive $85.00 per share. The merger, approved unanimously by Crinetics' board, is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals.